Naureen Quibria

Stock Analyst at Capital One

(n/a)

# 4,439

Out of 4,835 analysts

9

Total ratings

12.5%

Success rate

-46.88%

Average return

Main Sectors:

Top Industries:

Stocks Rated by Naureen Quibria

	Stock	Action	Price Target	Current	Upside	Ratings	Updated
	BMEA Biomea Fusion	Initiates: Overweight	$25	$1.52	+1,544.74%	1	Aug 29, 2024
	IMMP Immutep	Initiates: Overweight	$10	$2.03	+392.61%	1	May 17, 2024
	ERAS Erasca	Initiates: Overweight	$8	$1.29	+522.57%	1	Mar 11, 2024
	CARM Carisma Therapeutics	Initiates: Overweight	$10	$0.17	+5,909.62%	1	Oct 3, 2023
	IMCR Immunocore Holdings	Initiates: Overweight	$84	$30.36	+176.68%	1	Aug 16, 2023
	DAWN Day One Biopharmaceuticals	Initiates: Overweight	$40	$6.25	+540.00%	1	Feb 8, 2023
	FENC Fennec Pharmaceuticals	Initiates: Overweight	$11	$6.81	+61.53%	1	Sep 7, 2022
	GNTA Genenta Science	Initiates: Buy	$21	$4.25	+394.12%	1	Jan 13, 2022
	KZIA Kazia Therapeutics	Initiates: Buy	$900	$3.59	+24,969.64%	1	Oct 14, 2021

Biomea Fusion

Aug 29, 2024

Initiates: Overweight

Price Target: $25

Current: $1.52

Upside: +1,544.74%

Immutep

May 17, 2024

Initiates: Overweight

Price Target: $10

Current: $2.03

Upside: +392.61%

Erasca

Mar 11, 2024

Initiates: Overweight

Price Target: $8

Current: $1.29

Upside: +522.57%

Carisma Therapeutics

Oct 3, 2023

Initiates: Overweight

Price Target: $10

Current: $0.17

Upside: +5,909.62%

Immunocore Holdings

Aug 16, 2023

Initiates: Overweight

Price Target: $84

Current: $30.36

Upside: +176.68%

Day One Biopharmaceuticals

Feb 8, 2023

Initiates: Overweight

Price Target: $40

Current: $6.25

Upside: +540.00%

Fennec Pharmaceuticals

Sep 7, 2022

Initiates: Overweight

Price Target: $11

Current: $6.81

Upside: +61.53%

Genenta Science

Jan 13, 2022

Initiates: Buy

Price Target: $21

Current: $4.25

Upside: +394.12%

Kazia Therapeutics

Oct 14, 2021

Initiates: Buy

Price Target: $900

Current: $3.59

Upside: +24,969.64%